Lidocaine for Fibromyalgia Sleep and Life Quality

IV Lidocaine Improves Fibromyalgia Pain and Sleep, But Benefits Differ

A new study finds that intravenous lidocaine can significantly reduce pain and improve sleep for people with fibromyalgia, but the sleep benefits may be more short-lived. Research by Halil Ibrahim Altun and Fatma Aysen Eren, published in the Journal of Clinical Medicine, followed 51 patients for three months after treatment. Their work shows a clear link between managing pain, improving sleep, and enhancing overall quality of life in this complex condition.

How the Study Was Conducted

The researchers performed a retrospective analysis of patients at a tertiary pain clinic. All participants had a confirmed fibromyalgia diagnosis and reported poor sleep, defined by a Pittsburgh Sleep Quality Index (PSQI) score greater than 5. The group was predominantly female (92.2%), with an average age of 41.6 years.

Each patient received intravenous lidocaine infusions as part of their standard clinical care. The team then compared scores from several validated questionnaires taken before treatment with scores taken one month and three months afterward. They measured pain intensity (NRS-11), fibromyalgia impact on daily life (FIQ), general mental and physical health (SF-12), and sleep quality (PSQI). Statistical tests determined if the changes were significant and how different factors, like pain and sleep, were related.

Significant Gains in Pain, Function, and Sleep

The results were positive. At both the one-month and three-month check-ins, patients reported statistically significant improvements across the board.

Pain intensity scores dropped. The impact of fibromyalgia on daily function, measured by the FIQ, decreased substantially. Scores on the SF-12, which measures quality of life, rose for both mental and physical components. Critically, sleep quality scores on the PSQI also showed marked improvement at the one-month mark.

However, the data revealed an important nuance. While pain relief and functional gains held relatively steady at three months, the improvement in sleep quality attenuated. Sleep was better than baseline but had declined from the peak benefit seen at one month.

The Interplay Between Pain, Sleep, and Long-Term Outcomes

The correlation analysis provided deeper insight into what drives improvement. The researchers found a negative correlation between pain scores and quality of life: lower pain was associated with better physical and mental health scores. They also found a positive correlation between fibromyalgia impact and poor sleep.

This led to a key conclusion. Improvements in sleep quality appeared most strongly linked to short-term functional gains. In contrast, the level of pain relief a patient achieved was more closely associated with their clinical status in the mid-term, at three months.

“Sleep quality appeared to be associated with short-term functional outcomes, whereas pain intensity was associated with mid-term clinical status,” the authors wrote. This suggests that while sleep and pain are deeply connected, they may influence the treatment timeline in different ways.

Practical Implications for Fibromyalgia and Related Conditions

This study supports the use of IV lidocaine as a potential treatment option for fibromyalgia, particularly for pain that disrupts sleep and daily function. The findings highlight the need for ongoing, multi-faceted management. The waning sleep benefit suggests that a single treatment may not be a permanent solution and that combining lidocaine with sustained sleep-focused therapies could be more effective.

For a population interested in hearing health, this research is highly relevant. Fibromyalgia has a well-documented comorbidity with conditions like tinnitus, hyperacusis, and misophonia. Central sensitization—a hyper-reactive nervous system—is a proposed mechanism in both fibromyalgia and these auditory hypersensitivity disorders. A treatment that calms systemic neural overactivity could theoretically benefit both pain and sound tolerance. Research into brain responses in misophonia and hyperacusis points to similar pathways of heightened central processing.

The focus on sleep is another critical intersection. Poor sleep exacerbates pain perception and can worsen auditory hypersensitivity. A treatment that breaks the cycle of pain and insomnia, even temporarily, can be a valuable tool. This aligns with broader health principles; for instance, resources like an evidence-based sleep hygiene guide are fundamental for managing chronic conditions. Furthermore, non-pharmacological interventions like manual therapy and exercises have shown promise for tinnitus, another condition often managed through multidisciplinary approaches.

Next Steps: The Need for Robust Trials

Altun and Eren are clear about the limitations of their work. As a retrospective observational study, it can show association but not prove causation. The lack of a control group makes it difficult to rule out placebo effects or the natural progression of symptoms.

The authors call for prospective, randomized controlled trials to confirm the findings. Future research must determine the optimal dose and schedule for IV lidocaine to maximize and sustain benefits, especially for sleep. Understanding who is most likely to respond to this treatment will also be important.

This study adds to the evidence that managing fibromyalgia requires attention to both pain and sleep. It offers a promising direction for a condition that shares significant ground with auditory processing disorders, suggesting that advances in understanding central sensitization in one area may inform treatment in another.

Source: Altun, H.I., & Eren, F.A. (2024). Evaluation of Changes in Sleep Quality and Quality of Life after Intravenous Lidocaine Treatment in Patients with Fibromyalgia. Journal of Clinical Medicine, 15(8), 2887. https://doi.org/10.3390/jcm15082887